Condition
Squamous Cell Skin Carcinoma
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Terminated1
Withdrawn1
Clinical Trials (2)
Showing 2 of 2 trials
NCT03773744Phase 1Withdrawn
MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
NCT01764607Phase 2TerminatedPrimary
Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma
Showing all 2 trials